Bayer cancer drug gets EU approval
November 18, 2013Sales and Marketing Bayer, CHMP, EU, Xtandi, Zytiga, xofigo
Bayer’s prostate cancer treatment Xofigo has been shown the green light by the European Commission. Xofigo (radium Ra 223 dichloride) …
Merck and J&J invest in Chinese manufacturing
November 18, 2013Manufacturing and Production J&J, JJ, Merck, manufacturing
Merck KGaA and Johnson & Johnson have both announced new manufacturing projects in China, suggesting investigations into corruption by the …
Lilly plans $700m insulin plant expansion programme
November 18, 2013Manufacturing and Production Taylor, lilly, manufacturing
Eli Lilly has said it will invest more than $700 million to expand its production capacity for insulin products in …
UK agency urged to ‘press’ EMA on speed reviews
November 18, 2013Research and Development, Sales and Marketing BIA, EMA, EU, MHRA
A new advisory group for the UK drugs regulator wants Europe to follow the lead of the US by introducing …
NICE tells pharma: don’t blame us for rejections
November 18, 2013Sales and Marketing Dillon, NHS, NICE, VBP
The head of NICE has publicly defended his agency against more pharma criticism but admits that it can make changes …
Pharma facility news in brief
November 18, 2013Manufacturing and Production Actavis, Bend Research and WuXi PharmaTech, China Pharma, GlaxoSmithKline, manufacturing, nibs
GlaxoSmithKline is planning to boost in-house production of pharmaceuticals in India by building a brand new facility with an investment …
Several leadership changes at Bristol-Myers Squibb
November 18, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS
BMS has made several modifications to its senior management team with appointments and role shuffles being the order of the …
Is the NHS in safe hands?
November 18, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hunt, Lansley, McConaghie, NHS
A total of 16 months have passed since Jeremy Hunt took over as health secretary from Andrew Lansley, and in …
Most health apps have ‘limited value’
November 15, 2013Medical Communications, Sales and Marketing Android, digital, healthcare apps, smartphone apple
In a challenge to pharma marketers everywhere, a new report has declared that the ‘vast majority’ of health-related apps aimed …
‘Old fashioned’ doctors in new GP contract
November 15, 2013Sales and Marketing BMA, GP, Hunt, Labour, NHS, UK, doctors
The government is changing GPs’ contract with the NHS in a bid to “bring back old-fashioned family doctors” who will …
Pharma slams PPRS deal
November 15, 2013Medical Communications, Sales and Marketing ABPI, PPRS, VBP, telegraph
The fallout from last week’s new drug pricing plan in the UK is continuing as nine pharma firms write an …
Questcor adds Elan president to its Board
November 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Elan, Questcor, martin
Biopharma firm Questcor Pharmaceuticals has appointed Elan’s president and chief executive G. Kelly Martin to its Board of directors. Martin has …
Roche signs $17 million immatics deal
November 15, 2013Research and Development, Sales and Marketing Cancer, Roche, immatics, lung, prostate
Roche is to pay German biotech company immatics $17 million to collaborate on the search for vaccines in various cancers, …
J&J ‘to pay out $4 billion’ in fresh legal case
November 14, 2013Sales and Marketing J&J, JJ, Risperdal, fines, hip replacement
Johnson & Johnson is set to pay up to $4 billion to settle thousands of legal cases related to patients …
Philippines typhoon: pharma response
November 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Philippines typhoon, pharma
Staff from pharma companies on the ground in the Philippines appear to have escaped the worst following the typhoon which …
Janssen/Pharmacyclics gain FDA nod for Imbruvica
November 14, 2013Sales and Marketing FDA, Janssen, Pharmacyclics, Revlimid, Velcade
The FDA has approved Janssen and Pharmacyclics’ Imbruvica to treat patients with mantle cell lymphoma (MCL), a rare and aggressive …
EMA delays data transparency
November 14, 2013Medical Communications, Research and Development, Sales and Marketing EMA, FDA, all trials, transparency
The European Medicines Agency has delayed its much-trailed plan to launch a clear policy on making clinical trial data publically …
ISPE names vice president of Europe
November 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ISPE
The International Society for Pharmaceutical Engineering which is the world’s largest not-for-profit association, has appointed former Boehringer head Dr Thomas …
Dendreon slashes more jobs
November 13, 2013Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Dendreon, Provenge, cuts
Another 150 jobs are to go at Dendreon Corporation as the company seeks to cut $125 million per year in …
GSK heart disease drug fails late-stage trial
November 13, 2013Sales and Marketing GSK, darapladib, heart, statin
GSK has said its investigational chronic coronary heart disease pill darapladib has failed to meet its primary endpoint in a …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
